Trials on three continents and involving about 3,900 volunteers found that the vaccine was “safe but did not provide protection” against HIV infection.
U.S. researchers Wednesday HIV vaccine only It was in the final stages of clinical trials.
the vaccine was being studied by a pharmaceutical company Janssen is part of multinational corporation Johnson & Johnson and the U.S. government and is frozen in Phase 3 of a clinical trial, the National Institutes of Health (NIH) said in a statement. bottom.
The trial held in With approximately 3,900 volunteers on three continents, They found the vaccine was “safe but did not offer protection against HIV infection,” the statement explained.
The vaccine study, known as Mosaic, began in 2019 and included the participation of cisgender men and transgender people between the ages of 18 and 60.
The decision to discontinue the study Independent Data Oversight Board determined that the vaccine did not meet the requirements.
What did the HIV vaccine under investigation look like?
According to the NIH, the vaccine was based on a “mosaic” of immunogens and aimed to induce the immune system’s response to combat different HIV variants.
Anthony Fauci, a top U.S. epidemiologist, said the news of the study suspension was “disappointing” But according to US media, research into a vaccine against HIV should not be given up.
This was agreed by Mitchell Warren, executive director of AVAC, an organization for HIV prevention, who also expressed dissatisfaction with the findings of the study.
“The hard truth is that the science to develop an HIV vaccine is very difficult, but now is not the time to back down from ongoing research,” the activist said in a statement.
According to United Nations statistics, more than 38 million people are currently infected with the HIV virus worldwide. In 2021 alone, he reported 1.5 million new infections globally.